Vertex Pharmaceuticals Inc / Ma: Form 10-Q for the period ended Sep 30, 2013
Filed with the SEC on Nov 7, 2013 and accepted by EDGAR at Nov 7, 2013, 21:22 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2013-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2013-07-01 to 2013-09-30 | $221.7m | us-gaap:Revenues |
| Revenue | 9 months2013-01-01 to 2013-09-30 | $860.8m | us-gaap:Revenues |
| Cost of revenue | 3 months2013-07-01 to 2013-09-30 | $20.0m | us-gaap:CostOfGoodsSold |
| Cost of revenue | 9 months2013-01-01 to 2013-09-30 | $75.7m | us-gaap:CostOfGoodsSold |
| Research and development | 3 months2013-07-01 to 2013-09-30 | $228.6m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2013-01-01 to 2013-09-30 | $669.2m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2013-07-01 to 2013-09-30 | $87.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2013-01-01 to 2013-09-30 | $287.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2013-07-01 to 2013-09-30 | −$134.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2013-01-01 to 2013-09-30 | −$629.3m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2013-07-01 to 2013-09-30 | −$751.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2013-01-01 to 2013-09-30 | −$132.9m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2013-07-01 to 2013-09-30 | −$124.1m | us-gaap:NetIncomeLoss |
| Net income | 9 months2013-01-01 to 2013-09-30 | −$489.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2013-07-01 to 2013-09-30 | −$0.54 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2013-01-01 to 2013-09-30 | −$2.20 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2013-07-01 to 2013-09-30 | −$0.54 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2013-01-01 to 2013-09-30 | −$2.20 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2013-07-01 to 2013-09-30 | 230,505,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2013-01-01 to 2013-09-30 | 222,764,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2013-01-01 to 2013-09-30 | −$80.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2013-01-01 to 2013-09-30 | $36.9m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2013-09-30 | $583.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2013-09-30 | $1.65bn | us-gaap:AssetsCurrent |
| Total assets | At period end2013-09-30 | $2.58bn | us-gaap:Assets |
| Current liabilities | At period end2013-09-30 | $409.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2013-09-30 | $1.10bn | us-gaap:Liabilities |
| Shareholders' equity | At period end2013-09-30 | $1.26bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000875320-13-000045. Last ingested by Listed: Nov 6, 2026, 12:56 ET. Listed shows no prices and gives no investment advice.